Valvular & structural heart disease
Late Clinical Outcomes of Balloon-Expandable Valves in Small Annuli: Results From the PARTNER Trials
Authors' conclusion
Five-year clinical outcomes were excellent and comparable between patients with small vs large aortic annuli. Outcomes in patients with small annuli were not affected by 30-day MG or PPM.
Study context
- Population
- Intermediate- and low-risk patients undergoing transcatheter aortic valve replacement (TAVR) with a balloon-expandable valve (PARTNER 2 S3 registry, PARTNER 3 RCT)
- Participants
- 1,355 participants
- Comparison
- Small vs large aortic annuli after TAVR
- Small annulin = 476
- Large annulin = 879reference
- Outcome
- Composite of:
- All-cause death
- Disabling stroke
- HF hospitalization
- Follow-up
- 5 years
Pooled result
As reported in the abstract
Death, disabling stroke or HF hospitalization
- Primary endpoint rates similar, small vs large annuli: 36.3% vs 35.8%
- P = 0.83
Further pooled results
Primary endpoint at 1 year
P = 0.94
Bioprosthetic valve failure · 5 years
P = 0.46
Primary endpoint, female patients (subgroup)
P = 0.90
- Primary endpoint at 1 year — Primary endpoint rates similar, small vs large annuli: 7.8% vs 8.0%
- P = 0.94
- Bioprosthetic valve failure — Infrequent in both groups: 2.9% vs 2.1%
- P = 0.46
5-year outcomes vs prosthesis-patient mismatch (PPM) and 30-day mean gradient (MG) (small annuli)
- No association with any severity of PPM
- P = 0.22
- No association with 30-day MG
- P for nonlinearity = 0.96
Safety
Bioprosthetic valve failure · 5 years
P = 0.46
Original publication
Late Clinical Outcomes of Balloon-Expandable Valves in Small Annuli: Results From the PARTNER Trials. JACC Cardiovasc Interv. Published 24 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →